{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:16:32Z","timestamp":1760368592364},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[1992,6,1]],"date-time":"1992-06-01T00:00:00Z","timestamp":707356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1992,6]]},"DOI":"10.1007\/bf02245165","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T15:38:36Z","timestamp":1133451516000},"page":"379-384","source":"Crossref","is-referenced-by-count":58,"title":["5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model"],"prefix":"10.1007","volume":"107","author":[{"given":"G. A.","family":"Kennett","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"BF02245165_CR1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.2042-7158.1987.tb03452.x","volume":"39","author":"BS Alexander","year":"1987","unstructured":"Alexander BS, Wood MD (1987) Stereoselective blockade of central (3-H) 5-Hydroxytryptamine binding to multiple sites (5-HT1A, 5-HT1B and 5-HT1C) by mianserin and propranolol. J Pharm Pharmacol 39:664\u2013666","journal-title":"J Pharm Pharmacol"},{"key":"BF02245165_CR2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0091-3057(86)90455-7","volume":"24","author":"HC Becker","year":"1986","unstructured":"Becker HC (1986) Comparison of the effects of the benzodiazepine midazolam and three serotonin antagonists on a consummatory conflict paradigm. Pharmacol Biochem Behav 24:1057\u20131064","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02245165_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-2999(88)90005-2","volume":"150","author":"TP Blackburn","year":"1988","unstructured":"Blackburn TP, Thornber CW, Pearce RJ, Cox B (1988) In vitro studies with ICI 169 369, a chemically novel 5-HT antagonist. Eur J Pharmacol 150:247\u2013256","journal-title":"Eur J Pharmacol"},{"key":"BF02245165_CR4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.2042-7158.1981.tb13841.x","volume":"34","author":"S Caccia","year":"1981","unstructured":"Caccia S, Ballabio M, Samanin R (1981) m-Chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 34:477\u2013478","journal-title":"J Pharm Pharmacol"},{"key":"BF02245165_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-2007-1017385","volume":"18","author":"DLS Ceulemans","year":"1985","unstructured":"Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303\u2013305","journal-title":"Pharmacopsychiatry"},{"key":"BF02245165_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00215473","volume":"92","author":"DS Charney","year":"1987","unstructured":"Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy patients. Psychopharmacology 92:14\u201321","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR7","first-page":"59","volume":"242","author":"BV Clineschmidt","year":"1979","unstructured":"Clineschmidt BV, Flataker LM, Faison E, Holmes R (1979) An in vivo model for investigating \u03b11 and \u03b12-receptors in the CNS: studies with mianserin. Arch Int Pharmacodyn 242:59\u201376","journal-title":"Arch Int Pharmacodyn"},{"key":"BF02245165_CR8","first-page":"327","volume":"227","author":"ML Cohen","year":"1983","unstructured":"Cohen ML, Fuller RW, Kurz KD (1983) LY 53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneous hypertensive rat. J Pharmacol Exp Ther 227:327\u2013332","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245165_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00431683","volume":"86","author":"FC Colpaert","year":"1985","unstructured":"Colpaert FC, Meert TF, Niemegeers CJE, Janssen PAJ (1985) Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in the rat. Psychopharmacology 86:45\u201354","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR10","first-page":"552","volume":"242","author":"PJ Conn","year":"1987","unstructured":"Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J Pharmacol Exp Ther 242:552\u2013557","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245165_CR11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/030006057900700405","volume":"7","author":"L Conti","year":"1979","unstructured":"Conti L, Pinder RM (1979) A controlled comparative trial of mian-serin and diazepam in the treatment of anxiety states in psychiatric outpatients. J Int Med Res 7:285\u2013289","journal-title":"J Int Med Res"},{"key":"BF02245165_CR12","first-page":"1","volume-title":"Mechanisms of action of benzodiazepines","author":"L Cook","year":"1975","unstructured":"Cook L, Sepinwall J (1975) Behavioural analysis of the effects and mechanisms of action of benzodiazepines. In: Costa E, Greengard P (eds) Mechanisms of action of benzodiazepines. Raven Press, New York, pp 1\u201328"},{"key":"BF02245165_CR13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.2042-7158.1988.tb05254.x","volume":"40","author":"B Costall","year":"1988","unstructured":"Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (1988) Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40:302\u2013305","journal-title":"J Pharm Pharmacol"},{"key":"BF02245165_CR14","unstructured":"Deacon R, Gardner CF (1986) Benzodiazepine and 5-HT ligands in a rat conflict test. Br J Pharmacol 88:330P"},{"key":"BF02245165_CR15","first-page":"429","volume-title":"Metabolic disorders of the nervous system","author":"SE File","year":"1981","unstructured":"File SE (1981) Behavioural effects of serotonin depletion. In: Clifford Rose E (ed) Metabolic disorders of the nervous system. Pitmans, London, pp 429\u2013445"},{"key":"BF02245165_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000118163","volume":"13","author":"SE File","year":"1985","unstructured":"File SE (1985) Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology 13:55\u201362","journal-title":"Neuropsychobiology"},{"key":"BF02245165_CR17","unstructured":"Gadie B, Lane AC, McCarthy PS, Tulloch IF, Walter DS (1983) 2-Alkyl analogues of RX 781094: potent selctive antagonists at central \u03b12-adrenoceptors. Br J Pharmacol 78:312P"},{"key":"BF02245165_CR18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/0091-3057(86)90215-7","volume":"24","author":"CR Gardner","year":"1986","unstructured":"Gardner CR (1986) Recent developments in 5-HT-related pharmacology of of animal models of anxiety. Pharmacol Biochem Behav 24:1479\u20131485","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02245165_CR19","first-page":"809","volume":"250","author":"S Gleeson","year":"1989","unstructured":"Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE (1989) Behavioural studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250:809\u2013817","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245165_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0014-2999(89)90802-9","volume":"168","author":"RA Glennon","year":"1989","unstructured":"Glennon RA, El-Kader A, Ismaiel M, McCarthy BG, Peroutka SJ (1989) Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur J Pharmacol 168:387\u2013392","journal-title":"Eur J Pharmacol"},{"key":"BF02245165_CR21","first-page":"344","volume":"189","author":"FG Graeff","year":"1974","unstructured":"Graeff FG (1974) Tryptamine antagonists and punished behaviour. J Pharmacol Exp Ther 189:344\u2013350","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245165_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF00432224","volume":"86","author":"FG Graeff","year":"1985","unstructured":"Graeff FG, Zuarde AW, Giglio JS, Lima Filho EC, Karniol IG (1985) Effect of metergoline on human anxiety. Psychopharmacology 86:334\u2013338","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000118187","volume":"13","author":"AP Guy","year":"1985","unstructured":"Guy AP, Gardner CR (1985) Pharmacological characterization of a modified social interaction model of anxiety in the rat. Neuropsychobiology 13:194\u2013201","journal-title":"Neuropsychobiology"},{"key":"BF02245165_CR24","first-page":"72","volume-title":"Peripheral actions of 5-HT","author":"D Hoyer","year":"1989","unstructured":"Hoyer D (1989) 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In: Fozard J (ed) Peripheral actions of 5-HT. Oxford University Press, Oxford, pp 72\u201399"},{"key":"BF02245165_CR25","unstructured":"Hoyer D (1990) Competitive antagonism by recognised 5-HT2 receptor antagonists at 5-HT1C receptors. Naunyn Schmiedeberg's Arch Pharmacol 341:Suppl R88"},{"key":"BF02245165_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-8993(86)90902-9","volume":"376","author":"D Hoyer","year":"1986","unstructured":"Hoyer D, Pazos A, Probst A, Palacios JM (1986) Serotonin receptors in the human brain. 1. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res 376:85\u201396","journal-title":"Brain Res"},{"key":"BF02245165_CR27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1476-5381.1988.tb11489.x","volume":"93","author":"BJ Jones","year":"1988","unstructured":"Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR 38032F, a 5-HT3-receptor antagonist. Br J Pharmacol 93:985\u2013993","journal-title":"Br J Pharmacol"},{"key":"BF02245165_CR28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0006-3223(88)90091-1","volume":"23","author":"RS Kahn","year":"1988","unstructured":"Kahn RS, Van Praag HM, Wetzler S, Asnis GM, Barr G (1988) Serotonin and anxiety revisited. Biol Psychiatry 23:189\u2013208","journal-title":"Biol Psychiatry"},{"key":"BF02245165_CR29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF02244603","volume":"100","author":"RS Kahn","year":"1990","unstructured":"Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, Van Praag HM (1990) Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology 100:339\u2013344","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1476-5381.1988.tb11508.x","volume":"94","author":"GA Kennett","year":"1988","unstructured":"Kennett GA, Curzon G (1988a) Evidence that mCPP may have behavioural effects mediated by 5-HT1C receptors. Br J Pharmacol 94:137\u2013147","journal-title":"Br J Pharmacol"},{"key":"BF02245165_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02431539","volume":"96","author":"GA Kennett","year":"1988","unstructured":"Kennett GA, Curzon G (1988b) Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia by RU 24969 only requires 5-HT1B receptors. Psychopharmacology 96:93\u2013100","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR32","first-page":"4","volume":"4","author":"GA Kennett","year":"1990","unstructured":"Kennett GA, Blackburn TP (1990) Anxiolytic-like actions of BRL 46470A \u2014 a novel 5-HT3 receptor antagonist. J Psychopharmacology 4:4","journal-title":"J Psychopharmacology"},{"key":"BF02245165_CR33","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/j.1476-5381.1991.tb12369.x","volume":"103","author":"GA Kennett","year":"1991","unstructured":"Kennett GA, Curzon (1991) Potencies of antagonists indicate that 5-HT1C receptors mediate 1\u20133(chlorophenyl) piperazine-induced hypophagia. Br J Pharmacol 103:2016\u20132020","journal-title":"Br J Pharmacol"},{"key":"BF02245165_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(87)90561-9","volume":"141","author":"GA Kennett","year":"1987","unstructured":"Kennett GA, Dourish CT, Curzon G (1987) 5-HT1B agonists induce anorexia at a postsynaptic site. Eur J Pharmacol 141:137\u2013147","journal-title":"Eur J Pharmacol"},{"key":"BF02245165_CR35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0014-2999(89)90252-5","volume":"164","author":"GA Kennett","year":"1989","unstructured":"Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164:445\u2013454","journal-title":"Eur J Pharmacol"},{"key":"BF02245165_CR36","unstructured":"Kennett GA, Whitton P, Curzon G (1990) ID50 values of antagonists vs mCPP-induced hypophagia and 5-HT2-mediated headshakes indicate that 5-HT1C sites mediate the hypophagia. Br J Pharmacol 99:241P"},{"key":"BF02245165_CR37","doi-asserted-by":"crossref","first-page":"213S","DOI":"10.1111\/j.1365-2125.1983.tb05868.x","volume":"15","author":"MC Khan","year":"1983","unstructured":"Khan MC, Bennie EH, Stulemeijer SM, Ravens MA (1983) Mianserin and doxepin in the treatment of outpatient depression with anxiety. Br J Clin Pharmacol 15:213S-218S","journal-title":"Br J Clin Pharmacol"},{"key":"BF02245165_CR38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/330746a0","volume":"330","author":"GJ Kilpatrick","year":"1988","unstructured":"Kilpatrick GJ, Jones BJ, Tyers MB (1988) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330:746\u2013749","journal-title":"Nature"},{"key":"BF02245165_CR39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00427500","volume":"80","author":"CML Leone","year":"1983","unstructured":"Leone CML, De Aguir JC, Graeff FG (1983) Role of 5-hydroxytryptamine in amphetamine effects on punished and unpunished behaviour. Psychopharmacology 80:78\u201382","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR40","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0024-3205(81)90747-5","volume":"28","author":"JE Leysen","year":"1981","unstructured":"Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R41 468, a novel antagonist of 5-HT2 receptors. Life Sci 28:1015\u20131022","journal-title":"Life Sci"},{"key":"BF02245165_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00505480","volume":"321","author":"LL Martin","year":"1982","unstructured":"Martin LL, Sanders-Bush E (1982) Comparison of the pharmacological characteristics of 5-HT1 and 5-HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn-Schmiedeberg's Arch Pharmacol 321:165\u2013170","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"BF02245165_CR42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00215475","volume":"92","author":"P Mason","year":"1987","unstructured":"Mason P, Skinner J, Luttinger D (1987) Two tests in rats for antianxiety effect of clinically anxiety attenuating antidepressants. Psychopharmacology 92:30\u201333","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-61-6-1179","volume":"61","author":"EA Mueller","year":"1985","unstructured":"Mueller EA, Murphy DL, Sunderland T (1985) Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist in humans. J Clin Endocrinol Metab 61:1179\u20131184","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02245165_CR44","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1111\/j.1365-2125.1978.tb04581.x","volume":"5","author":"JE Murphy","year":"1978","unstructured":"Murphy JE (1978) Mianserin in the treatment of depressive illness and anxiety states in general practice. Br J Clin Pharmacol 5:81S-85S","journal-title":"Br J Clin Pharmacol"},{"key":"BF02245165_CR45","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/0006-2952(89)90319-5","volume":"10","author":"DR Nelson","year":"1989","unstructured":"Nelson DR, Thomas DR (1989) (3-H)-BRL 43694 (Granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem Pharmacol 10:1693\u20131695","journal-title":"Biochem Pharmacol"},{"key":"BF02245165_CR46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00491478","volume":"319","author":"VS Nicholson","year":"1982","unstructured":"Nicholson VS, Wieringa JH, Van Delft AML (1982) Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmiedeberg's Arch Pharmacol 319:48\u201355","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"BF02245165_CR47","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/0028-3908(82)90144-7","volume":"21","author":"RJM Niesink","year":"1982","unstructured":"Niesink RJM, Van Ree JM (1982) Antidepressant drugs normalise the increased social behaviour of pairs of male rats induced by short term isolation. Neuropharmacology 21:1343\u20131348","journal-title":"Neuropharmacology"},{"key":"BF02245165_CR48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0006-3223(91)90264-M","volume":"29","author":"TA Pigott","year":"1990","unstructured":"Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch RC, Murphy DL (1990) Metergoline blocks the behavioural and neuroendocrine effects of orally administered mCPP in obsessive-compulsive disorder. Biol Psychiatry 29:418\u2013426","journal-title":"Biol Psychiatry"},{"key":"BF02245165_CR49","unstructured":"Piper D, Upton N, Thomas DL, Nicholass J (1988) The effects of 5-HT3 receptor antagonists BRL 43694 and GR 38032F in animal models of anxiety. Br J Pharmacol 94:314P"},{"key":"BF02245165_CR50","first-page":"57S","volume":"5","author":"GFM Russell","year":"1978","unstructured":"Russell GFM, Niaz U, Wakeling A, Slade PD (1978) Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness. Br J Clin Pharmacol 5:57S-65S","journal-title":"Br J Clin Pharmacol"},{"key":"BF02245165_CR51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/BF00168661","volume":"339","author":"P Schoeffter","year":"1989","unstructured":"Schoeffter P, Hoyer D (1989a) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedeberg's Arch Pharmacol 339:675\u2013682","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"BF02245165_CR52","first-page":"285","volume":"340","author":"P Schoeffter","year":"1989","unstructured":"Schoeffter P, Hoyer D (1989b) 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some \u03b2-adrenoceptor antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 340:285\u2013292","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"BF02245165_CR53","first-page":"485.21","volume":"15","author":"JP Seibyl","year":"1989","unstructured":"Seibyl JP, Krystal JH, Price LH, Woods SW, Heninger GR, Charney DS (1989) 5-HT function in the biochemical and behavioural responses to mCPP in healthy subjects and schizophrenics. Am Soc Neurosci Abstr 15:485.21","journal-title":"Am Soc Neurosci Abstr"},{"key":"BF02245165_CR54","first-page":"3024","volume":"39","author":"J Sepinwall","year":"1980","unstructured":"Sepinwall J, Cook L (1980) Mechanism of action of the benzodiazepines: Behavioral aspect. Fed Proc 39:3024\u20133031","journal-title":"Fed Proc"},{"key":"BF02245165_CR55","first-page":"480","volume":"231","author":"MA Sills","year":"1984","unstructured":"Sills MA, Wolfe BB, Frazer A (1984) Determination of selective and non-selective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 231:480\u2013487","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245165_CR56","first-page":"29","volume-title":"Mechanism of action of benzodiazepines","author":"L Stein","year":"1975","unstructured":"Stein L, Wise CD, Belluzzi JD (1975) Effects of benzodiazepines on central serotonergic mechanisms. In: Costa E, Greengard P (eds) Mechanism of action of benzodiazepines. Raven Press, New York, pp 29\u201344"},{"key":"BF02245165_CR57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(84)90714-3","volume":"106","author":"MD Tricklebank","year":"1984","unstructured":"Tricklebank MD, Forler C, Fozard J (1984) The involvement of subtypes of the 5-HT1A receptor and of catecholaminergic systems in the behavioural response to 8-Hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106:271\u2013277","journal-title":"Eur J Pharmacol"},{"key":"BF02245165_CR58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF02245806","volume":"100","author":"P Whitton","year":"1990","unstructured":"Whitton P, Curzon G (1990) Anxiogenic-like effect of infusing 1-(3-chlorophenyl)piperazine (mCPP) into the hippocampus. Psychopharmacology 100:138\u2013140","journal-title":"Psychopharmacology"},{"key":"BF02245165_CR59","first-page":"147","volume":"197","author":"JD Winter","year":"1972","unstructured":"Winter JD (1972) Comparison of chlordiazepoxide, methysergide and cinanserin as modifiers of punished behaviour and as antagonists of N,N-dimethyltryptamine. Arch Int Pharmacodyn Ther 197:147\u2013159","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"BF02245165_CR60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-3223(87)90199-5","volume":"22","author":"J Zohar","year":"1987","unstructured":"Zohar J, Insel TR (1987) Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry 22:667\u2013687","journal-title":"Biol Psychiatry"},{"key":"BF02245165_CR61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archpsyc.1988.01800260081011","volume":"45","author":"J Zohar","year":"1987","unstructured":"Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987) Serotonergic responsivity in obsessive compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 45:167\u2013172","journal-title":"Arch Gen Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02245165\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T07:44:24Z","timestamp":1706773464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02245165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,6]]},"references-count":61,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[1992,6]]}},"alternative-id":["BF02245165"],"URL":"https:\/\/doi.org\/10.1007\/bf02245165","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,6]]}}}